Cromwell
Cromwell
Cromwell, Connecticut, United States24 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | anxiety disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 2 | 2026-10-06 | NCT07161700 | |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | anxiety disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07065240 | |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Phase 2 | 2026-09-24 | NCT07783542 | |
| Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04743141 | |
| Randomized Study in Children and Adolescents With Migraine: Acute Treatment | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04649242 | |
| An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 2 | 2026-09-23 | NCT07449702 | |
| Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder | Bipolar I or II Disorder | Active, not recruiting | Phase 2 | 2026-09-23 | NCT07220460 | |
| Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | Hyperalgesia, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Somatosensory Disorders, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, rheumatic disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07398417 | |
| An Open-Label Study of Azetukalner in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-03 | NCT06922110 | |
| A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder | Binge-Eating Disorder, Feeding and Eating Disorders, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-08-11 | NCT06878976 | |
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 2 | 2026-08-10 | NCT07474792 | |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06963021 | |
| Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, cardiovascular disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Not applicable | 2026-08-06 | NCT05908240 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-03 | NCT06775379 | |
| Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | Binge-Eating Disorder, Feeding and Eating Disorders, psychiatric disorder | Recruiting | Phase 3 | 2026-07-28 | NCT06413433 | |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-07-24 | NCT06966401 | |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-07-08 | NCT06958211 | |
| ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 2 | 2026-07-01 | NCT07090330 | |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-06-17 | NCT06846320 | |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Bipolar and Related Disorders, bipolar disorder, mood disorder, psychiatric disorder | Active, not recruiting | Phase 2 | 2026-05-26 | NCT06869187 | |
| A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 2 | 2026-03-20 | NCT06598462 | |
| A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 2 | 2026-02-13 | NCT05139602 | |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-01-20 | NCT06633016 | |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) | anxiety disorder, phobic disorder, psychiatric disorder, social phobia | Active, not recruiting | Phase 3 | 2025-11-26 | NCT06358651 |